What one share of Ironwood Pharmaceuticals holds
We are a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. We are focused on the development and commercialization of innovative product opportunities in areas of significant unmet need, leveraging our demonstrated expertise and capabilities in GI and rare diseases.
Ironwood Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.35 |
|---|---|
| Profit | $0.78 |
| Cash and investments | $0.48 |
| Debt | $1.21 |
| Book value | −$0.98 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $4.82 | −$10.00 | $0.50 | −$0.98 | — | −$41.92 |
| 2010 | $0.49 | −$0.59 | $0.19 | −$0.95 | — | $1.78 |
| 2011 | $0.66 | −$0.65 | $0.10 | −$0.85 | — | $1.10 |
| 2012 | $1.41 | −$0.68 | $0.13 | −$0.79 | — | $1.35 |
| 2013 | $0.20 | −$2.35 | $0.08 | −$2.44 | — | $0.33 |
| 2014 | $0.56 | −$1.39 | $0.03 | −$1.16 | — | $0.65 |
| 2015 | $1.05 | −$1.00 | $0.03 | −$0.78 | — | $0.67 |
| 2016 | $1.89 | −$0.56 | $0.03 | −$0.21 | — | $0.46 |
| 2017 | $2.00 | −$0.78 | $0.02 | −$0.69 | — | $0.07 |
| 2018 | $2.27 | −$1.85 | $0.00 | −$0.47 | — | −$1.27 |
| 2019 | $2.75 | $0.14 | $0.05 | $0.02 | — | −$0.59 |
| 2020 | $2.42 | $0.66 | $0.01 | $1.04 | — | $0.39 |
| 2021 | $2.52 | $3.21 | $0.00 | $1.59 | — | $3.74 |
| 2022 | $2.20 | $0.96 | $0.00 | $1.47 | — | $4.24 |
| 2023 | $2.85 | −$6.45 | $0.00 | $1.18 | — | −$2.21 |
| 2024 | $2.20 | $0.01 | $0.00 | $0.65 | — | −$1.88 |
| 2025 | $1.82 | $0.15 | $0.00 | $0.78 | — | −$1.61 |
Common questions about Ironwood Pharmaceuticals
How much does one share of Ironwood Pharmaceuticals earn?
Over the last 12 months, each share of Ironwood Pharmaceuticals earned $0.78 of profit on $2.35 of sales, keeping about 33¢ of every $1 (profit margin).
Does Ironwood Pharmaceuticals pay a dividend?
Ironwood Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Ironwood Pharmaceuticals’s book value per share?
Ironwood Pharmaceuticals’s book value is negative (−$0.98 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Ironwood Pharmaceuticals have?
Each share of Ironwood Pharmaceuticals has $0.48 of cash and investments and $1.21 of debt, as of June 30, 2026.
Has Ironwood Pharmaceuticals bought back shares?
Ironwood Pharmaceuticals’s share count rose about 2190% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.